Isangina
Isangina is a medicine that helps your heart by relaxing blood vessels, which reduces the heart's workload and helps it get more oxygen.
Form
tabletti
Strength
20 mg
Active Ingredient
Isosorbide mononitrate
Manufacturer
Merus Labs Luxco II S.à r.l.
How to Use
Dosage
For tablets: usually 1 tablet 2 or 3 times a day. For prolonged-release capsules: usually 1 or 2 capsules once a day, typically in the morning. Your doctor will tell you the exact dose.
Method
Swallow tablets whole or halved with water; do not chew. Swallow prolonged-release capsules whole with water; do not chew or crush.
Important
Always follow your doctor's instructions for the maximum daily dose. Do not take more than prescribed.
Possible Side Effects
COMMON
- •Headache
- •Dizziness or lightheadedness
- •Drowsiness
- •Fast heartbeat
- •Feeling dizzy when standing up
- •Weakness
RARE
- •Worsening chest pain
- •Fainting or passing out
- •Feeling sick or throwing up (nausea or vomiting)
- •Allergic skin reactions, like a rash
- •Flushing (redness of the face and neck)
- •Low blood pressure
- •Swelling of the face, tongue, or throat (angioedema), difficulty breathing or hives
- •Severe skin disease with widespread redness and peeling (exfoliative dermatitis)
Important Warnings
- Do not take Isangina if you are allergic to isosorbide mononitrate, other nitrate medicines, or any other ingredients in this medicine.
- Do not use Isangina if you are taking medicines for erectile dysfunction (like sildenafil, vardenafil, or tadalafil), as this can cause a dangerous drop in blood pressure.
- Avoid alcohol while taking Isangina, as it can make the blood pressure-lowering effect of Isangina stronger.
- Do not stop taking Isangina suddenly without talking to your doctor, as this can worsen your chest pain.
- Isangina can affect your ability to drive or operate machinery. Alcohol can increase this effect.
Use in Elderly Patients
Category A
Suitable for older adults. Consider reduced blood pressure and the risk of fainting due to orthostatic hypotonia. Need for long-acting product should be assessed regularly. (updated 19.5.2025)